🇺🇸 FDA
Patent

US 6310064

Aralkyl diazabicycloalkane derivatives for CNS disorders

expired A61KA61K31/495A61P

Quick answer

US patent 6310064 (Aralkyl diazabicycloalkane derivatives for CNS disorders) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 30 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/495, A61P, A61P25/18